Peripheral Matters | Dose-Reduced Direct Oral Anticoagulants: Practical Considerations - American College of Cardiology
Anticoagulation therapy in Atrial Fibrillation patients at high bleeding risk - It's Over 9000!
ELIQUIS® (apixaban) dosing for NVAF patients | ELIQUIS UK
The use of ELIQUIS® (apixaban) in various clinical populations - ppt download
Safety and effectiveness of reduced-dose apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A sub-analysis of the STANDARD study - ScienceDirect
![PDF] Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5e1119c2e7a1bbe9164d9b7f35ded4b0bab54995/2-Table1-1.png "PDF] Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. | Semantic Scholar")
PDF] Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. | Semantic Scholar
DVT Prophylaxis After Hip/Knee Surgery|ELIQUIS® (apixaban) Safety Info
ELIQUIS® (apixaban) dosing | patients with renal or hepatic impairment | ELIQUIS IRELAND
Direct Oral Anticoagulants are High-Risk Medications with Potentially Complex Dosing | PSNet
Target-Specific Oral Anticoagulants
Target-Specific Oral Anticoagulants
Sensitivity analyses of apixaban dose and bleeding | Download Table
Ashley & Brooke Barlow PharmD on Twitter: "DOACs are ⤴️ being used for a multitude of indications, keeping the dosing difference straight can be challenging ✨ Here's a quick Infographic to remember
ELIQUIS® (apixaban) dosing for NVAF patients | ELIQUIS UK
Apixaban - Uses | Dosage | Side Effects | Drug Warnings | and Precautions
Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions | SpringerLink
ELIQUIS® (apixaban) dosing | patients with renal or hepatic impairment | ELIQUIS IRELAND
Cureus | Expert Opinion on the Use of Novel Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation for the Primary Care Setting in India: A Literature Review | Article
Dose reduction criteria of NOACs 18 | Download Scientific Diagram
Frontiers | Off-Label Underdosing or Overdosing of Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis
Safety and effectiveness of reduced-dose apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A sub-analysis of the STANDARD study - ScienceDirect
JCM | Free Full-Text | Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO)
Target-Specific Oral Anticoagulants
Apixaban (Eliquis) for Stroke Prevention in Atrial Fibrillation | AAFP
Table 1 from Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical
